PMA device
TRUFILL n-BCA Liquid Embolic System
Cerenovus, Inc. · Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations (KGG, Class III) · First FDA decision Feb 28, 2023, newest Oct 23, 2026Brain bleeding (hemorrhagic stroke)
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
2
Naming "TRUFILL n-BCA Liquid"
MAUDE reports
0
Brand "TRUFILL n-BCA Liquid", since 2015
PubMed studies
0
Mentioning "TRUFILL n-BCA Liquid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TRUFILL n-BCA Liquid Embolic System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- TRUFILL n-BCA Liquid Embolic SystemPMA supplement
P990040-S037 · Decided Oct 23, 2026 · 263 days after receipt · Normal 180 Day Track No User Fee
Device type: tissue adhesive for use in embolization of brain arteriovenous malformations (KGG) · Neurology & Neurosurgery
- TRUFILL n-BCA Liquid Embolic SystemPMA supplement
P990040-S030 · Decided Feb 28, 2023 · 103 days after receipt · Normal 180 Day Track No User Fee
Device type: tissue adhesive for use in embolization of brain arteriovenous malformations (KGG) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "TRUFILL n-BCA Liquid", any status and sponsor, newest update first.
- MMA Embolization for Refractory Chronic MigraineActive, not recruiting
Cerenovus, Part of DePuy Synthes Products, Inc.Not on our public-company list
NCT06735833 · 31 participants · Start Apr 23, 2025 · Primary completion Dec 25, 2026
Device: Middle Meningeal Artery embolization · For: Migraine Disorders
Sites: Walnut Creek, California; Hartford, Connecticut; Buffalo, New York · 8 sites in all
- Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCAPivotal-lookingCompleted
Cerenovus, Part of DePuy Synthes Products, Inc.Not on our public-company list
NCT04816591 · 376 participants · Start May 27, 2021 · Primary completion Aug 15, 2024
Device: Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System; Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System · For: Chronic Subdural Hematoma
Sites: Birmingham, Alabama; Tucson, Arizona; Walnut Creek, California · 33 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TRUFILL n-BCA Liquid", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code KGG
86 reports: 22 malfunction, 60 injury, 4 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0788-2014 · Started Oct 11, 2013 · Posted by FDA Jan 23, 2014
Reason given: Incorrect instructions for use (IFU).
Cause as FDA categorized it: Employee error · Device type: Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations (KGG)
Z-0789-2014 · Started Oct 11, 2013 · Posted by FDA Jan 23, 2014
Reason given: Incorrect instructions for use (IFU).
Cause as FDA categorized it: Employee error · Device type: Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations (KGG)
Published research
The most relevant PubMed records for "TRUFILL n-BCA Liquid"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code KGG.
- TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic SystemCerenovus, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.